Belantamab mafodotin monotherapy for multiply-relapsed myeloma: a retrospective study from the United Kingdom and the Republic of Ireland
Watson, Edmund C R Djebbari, Faouzi Panitsas, Fotios Vallance, Grant Asher, Samir Saeed, Malahat Walker, Mairi Powell, Matthew Rampotas, Alexandros Leary, Heather
Watson, Edmund C R
Djebbari, Faouzi
Panitsas, Fotios
Vallance, Grant
Asher, Samir
Saeed, Malahat
Walker, Mairi
Powell, Matthew
Rampotas, Alexandros
Leary, Heather
Affiliation
University of Oxford; Oxford University Hospitals NHS Foundation Trust; General Hospital of Athens "LAIKO"; University College London Hospitals NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; NHS Greater Glasgow and Clyde; Cardiff and Vale University Health Board; North Tees and Hartlepool NHS Foundation Trust; Clatterbridge Cancer Centre NHS Foundation Trust; Manchester University NHS Foundation Trust; University Hospital Waterford; Belfast City Hospital; Worcestershire Acute Hospitals NHS Trust
Other Contributors
Publication date
2025-04-30
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Introduction: Belantamab mafodotin (belamaf) was the first BCMA-targeting immunotherapy licensed in myeloma and was available as monotherapy for a fifth or greater line of treatment. Outcomes for patients in the United Kingdom and the Republic of Ireland potentially differ from those of other regions and may illuminate factors predicting response to therapy.
Methods and results: We performed a retrospective study of patients treated with belamaf monotherapy in the United Kingdom and the Republic of Ireland. In our cohort of 88 patients, we saw an overall response rate (ORR) of 60%, a median progression-free survival (PFS) of 8.7 months and a median duration of response (DoR) of 15.8 months. The spectrum of adverse events was as expected, with 84% (71/85) of patients experiencing toxicity. Eye-related adverse events were the most common, affecting 66% (56/85), leading to dose reduction or delay in 41% (35/85) and discontinuation in 6% (5/85). We specifically assessed physician decision-making in the context of ocular side effects and found a relatively high frequency of the drug being administered despite moderate levels of toxicity.
Conclusion: Our cohort's ORR is significantly different from those of the DREAMM-2 and -3 trials and other real-world studies, though a long-duration response has been reported in other cohorts. Comparative analysis with other real-world studies did not reveal any significant factors predictive of ORR. The frequent administration of belamaf to patients with eye disease may well reflect a more pragmatic approach than was originally prescribed in the landmark trials.
Citation
Watson ECR, Djebbari F, Panitsas F, Vallance G, Asher S, Saeed M, Walker M, Powell M, Rampotas A, Leary H, Khera A, Atkinson A, Aung NN, Brearton G, Froggatt J, Hassadi EE, Gokkel E, Lawless S, Salhan B, Shafeek S, Lokare A, Stirling C, Oppermann U, Soutar R, Popat R, Kyriakou C, Ramasamy K. Belantamab Mafodotin Monotherapy for Multiply-Relapsed Myeloma: A Retrospective Study From the United Kingdom and the Republic of Ireland. EJHaem. 2025 Apr 30;6(3):e70039. doi: 10.1002/jha2.70039.
Type
Article